Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy

November 2023 in “ JAAD Case Reports ”

Olivia Katamanin, Peter Ch’en, Eingun James Song

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on jaadcasereports.org →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis

7 citations , April 2023 in “Frontiers in immunology”

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations , March 2023 in “American Journal of Clinical Dermatology”

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

research Ruxolitinib for the Treatment of Severe Alopecia Areata

37 citations , September 2018 in “Journal of the American Academy of Dermatology”

Ruxolitinib can help regrow hair in severe alopecia areata.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Related Research

1 / 1 results

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations , July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.